We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Dudley
Pennell
DJ.Pennell@rbht.nhs.uk
Dr
Ramyah
Rajakulasingam
r.rajakulasingam@rbht.nhs.uk
Ischaemic heart diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This research will use a novel heart scanning technique called Diffusion Tensor Cardiac Magnetic Resonance (DT-CMR) to assess changes in arrangement of heart muscle cells after a heart attack (ST-elevation myocardial infarction). The damage that occurs after a heart attack leads to heart enlargement and reduced pump function, which can result in heart failure, life threatening heart rhythm abnormalities and death. This study will examine changes in heart muscle architecture 3-5 days after a heart attack using DT-CMR, and assess whether this early measurement can identify patients who will later develop heart enlargement and reduced pump function at 4 months. These individuals are at highest risk of poor clinical outcomes. Early identification may provide opportunities to improve their treatment and reduce risk of future adverse events.
Furthermore, we will also investigate the relationship between disturbed heart muscle architecture following a heart attack, and changes in dimension and composition of heart muscle segments assessed by MRI, and blood markers of heart muscle injury. We will recruit patients treated for a heart attack from Harefield Hospital, which is a high-volume heart attack centre. Each patient will undergo a MRI scan at the CMR unit at the Royal Brompton Hospital 3-5 days and 4 months after heart attack using our new state of the art research scanner. We expect this study to occur over a 3-year period with recruitment of 75 patients.
This research will provide new insights into the mechanisms underlying changes in heart function after a heart attack and expand our understanding of the clinical utility of DT-CMR in these patients. This new knowledge may inform the development and evaluation of new treatments, and if our hypothesis is proven, it will provide the rationale for future studies to establish the role of DT-CMR in risk stratifying patients after a heart attack.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Unable to give consent or follow breathing instructions Prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass surgery Treatment with thrombolysis Presentation with resuscitated cardiac arrest, cardiogenic shock or use of intra-aortic balloon pump or impella device Bystander disease > 50% Atrial fibrillation High ventricular ectopic burden Claustrophobia Presence of CMR-contraindicated implanted devices e.g. pacemaker Estimated glomerular filtration rate < 30mL/min Clinical reason why a patient cannot undergo a CMR such as decompensated heart failure or difficulty building. Pregnant or breastfeeding women
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by BRITISH HEART FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41438
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
